Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594789 | 0.83 | TBXAS1 (0.51) | CES2CES1TBXAS1EPHX2PPARG | |
| SCHEMBL15905964 | 0.83 | TBXAS1 (0.51) | CES2CES1TBXAS1EPHX2PPARG | |
| SCHEMBL12142763 | 0.82 | CES2 (0.53) | CES2CES1EPHX2PPARGPTGS1 | |
| SCHEMBL3736020 | 0.82 | SLC7A5 (0.57) | CES2CES1PTGS1PTGS2LMNA | |
| SCHEMBL12142616 | 0.82 | SLC7A5 (0.57) | CES2CES1PTGS1PTGS2LMNA | |
| SCHEMBL11237591 | 0.82 | TBXAS1 (0.59) | TBXAS1FFAR1PTGS1PTGS2LMNA | |
| SCHEMBL16360424 | 0.81 | EPHX2 (0.47) | TBXAS1EPHX2PPARGFFAR1PTGS1 | |
| SCHEMBL14640265 | 0.80 | ALDH1A1 (0.55) | TBXAS1EPHX2PPARGPTGS1PTGS2 | |
| SCHEMBL12142803 | 0.79 | KMT2A (0.55) | TBXAS1EPHX2PPARGPTGS1PTGS2 | |
| SCHEMBL19485698 | 0.79 | KMT2A (0.55) | TBXAS1EPHX2PPARGPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8859802-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8846876-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Abrx, Inc. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8791231-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | CES2 3332/4885CES1 3673/4885TBXAS1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.